To order this detailed 670+ page report, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Key Inclusions
§ A detailed review of the overall landscape of
gene therapies and genome editing therapies, including information on various
drug / therapy developer companies, phase of development (marketed, clinical,
and preclinical / discovery stage) of pipeline candidates, key therapeutic
areas (cardiovascular disorders, muscular disorders, neurological disorders,
ocular disorders, oncology and others) and target disease indication(s),
information on gene type, type of vector used, type of therapy (ex vivo
and in vivo), mechanism of action, type of gene modification (gene
augmentation, oncolytic viral therapy and others) and special drug designation
(if any).
§ A discussion on the various types of viral and
non-viral vectors, along with information on design, manufacturing
requirements, advantages, limitations and applications of currently available
gene delivery vectors.
§ A world map representation, depicting the most
active geographies, in terms of the presence of companies engaged in developing
gene therapies, and a bull's eye analysis, highlighting the distribution of
clinical-stage pipeline candidates by phase of development, type of vector and
type of therapy (ex vivo and in vivo).
§ A discussion on the regulatory landscape
related to gene therapies across various geographies, namely North America (the
US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South
Korea), providing details related to the various challenges associated with
obtaining reimbursements for gene therapies.
§ Detailed profiles of marketed and phase II/III
and gene therapies, including a brief history of development, information on
current development status, mechanism of action, affiliated technology,
strength of patent portfolio, dosage and manufacturing details, along with
information on the developer company.
§ An elaborate discussion on the various
commercialization strategies that can be adopted by drug developers for use
across different stages of therapy development, namely prior to drug launch, at
/ during drug launch and post-marketing.
§ A review of various emerging technologies and
therapy development platforms that are being used to design and manufacture
gene therapies, featuring detailed profiles of technologies that were / are
being used for the development of four or more products / product candidates.
§ An in-depth analysis of the various patents
that have been filed / granted related to gene therapies and genome editing
therapies, since 2016. The analysis also highlights the key parameters
associated with the patents, including information on patent type (granted
patents, patent applications and others), publication year, regional
applicability, CPC classification, emerging focus areas, leading industry /
non-industry players (in terms of the number of patents filed / granted),
and patent valuation.
§ An analysis of the various mergers and
acquisitions that have taken place in this domain, highlighting the trend in
the number of companies acquired between 2014-2019. The analysis also provides
information on the key value drivers and deal multiples related to the mergers
and acquisitions that we came across.
§ An analysis of the investments made at various
stages of development in companies that are focused in this area, between
2014-2019, including seed financing, venture capital financing, IPOs, secondary
offerings, debt financing, grants and other offerings.
§ An analysis of the big biopharma players
engaged in this domain, featuring a heat map based on parameters, such as
number of gene therapies under development, funding information, partnership
activity and strength of patent portfolio.
§ A case study on the prevalent and emerging
trends related to vector manufacturing, with information on companies offering
contract services for manufacturing vectors. The study also includes a detailed
discussion on the manufacturing processes associated with various types of
vectors.
§ A discussion on the various operating models
adopted by gene therapy developers for supply chain management, highlighting
the stakeholders involved, factors affecting the supply of therapeutic products
and challenges encountered by developers across the different stages of the
gene therapy supply chain.
§ An analysis of the various factors that are
likely to influence the pricing of gene-based therapies, featuring different
models / approaches that may be adopted by manufacturers to decide the prices
of these therapies.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Key
therapeutic areas
§ Autoimmune
disorders
§ Cardiovascular
diseases
§ Genetic
disorders
§ Hematological
disorders
§ Metabolic
disorders
§ Ophthalmic
disorders
§ Oncological
disorders
§ Others
§
Type of vector
§ Adeno
associated virus
§ Adenovirus
§ Herpes
simplex virus type 1
§ Lentivirus
§ Plasmid
DNA
§ Retrovirus
§ Vaccinia
Virus
§ Type
of therapy
§ Ex vivo
§ In vivo
§ Type
of gene modification
§ Gene
augmentation
§ Immunotherapy
§ Oncolytic
therapy
§ Others
§ Route
of administration
§ Intraarticular
§ Intracerebellar
§ Intramuscular
§ Intradermal
§ Intravenous
§ Intravitreal
§ Intravesical
§ Subretinal
§ Others
§ Key
geographical regions
§ North
America
§ Europe
§ Asia-Pacific
The report includes
detailed transcripts of discussions held with the following experts:
§ Adam
Rogers (CEO, Hemera Biosciences)
§ Al
Hawkins (CEO, Milo Biotechnology)
§ Buel
Dan Rodgers (Founder & CEO, AAVogen)
§ Cedric
Szpirer (Executive & Scientific Director, Delphi Genetics)
§ Christopher
Reinhard (CEO and Chairman, Cardium Therapeutics)
§ Ryo
Kubota (Chairman, President and Chief Executive Officer, Acucela)
§ Jeffrey
Hung (CCO, Vigene Biosciences)
§ Marco
Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
§ Michael
Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
§ Robert
Jan Lamers (CEO, Arthrogen)
§ Tom
Wilton (Chief Business Officer, LogicBio Therapeutics)
To request sample pages, please visit https://www.rootsanalysis.com/reports/285/request-sample.html
Key
Questions Answered
§
Who are the leading industry players in this market?
§ How
big is the development pipeline and which new indications are coming in focus?
Which vectors are being used for effective delivery of the therapeutic agents?
§ Who
are the key investors in the gene therapy market?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§ What
kind of commercialization strategies are being adopted by gene therapy
developers?
§ What
are the different pricing models and reimbursement strategies used for gene
therapies?
§ What
are the prevalent R&D trends related to gene therapies?
§ What
are the various technology platforms that are either available in the market or
are being designed for the development of gene therapies?
§
Who are the key CMOs / CDMOs that claim to supply viral /
plasmid vectors for gene therapy development?
You may also be
interested in the following titles:
1. Viral Vectors,
Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition),
2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and
Other Vectors)
2. CAR-T Therapies Market (2nd Edition), 2019-2030
3.
Global T-Cell (CAR-T,
TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact
Us
Gaurav
Chaudhary
+1
(415) 800 3415
gaurav.chaudhary@rootsanalysis.com